| Recruiting | Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Subop Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis | Phase 3 | 2024-06-03 |
| Recruiting | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Endometrial Cancer | Phase 2 / Phase 3 | 2023-07-17 |
| Withdrawn | Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Ce Non Small Cell Lung Cancer | Phase 1 / Phase 2 | 2023-06-01 |
| Terminated | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage | Phase 2 | 2021-12-06 |
| Recruiting | KRT-232 and TKI Study in Chronic Myeloid Leukemia Chronic Myeloid Leukemia | Phase 1 / Phase 2 | 2021-05-07 |
| Unknown | Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF) | Phase 2 | 2021-04-13 |
| Unknown | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | 2021-02-23 |
| Unknown | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib i Myelofibrosis | Phase 1 / Phase 2 | 2021-01-28 |
| Unknown | KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intoleran Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis | Phase 1 / Phase 2 | 2020-11-17 |
| Terminated | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN) | Phase 1 / Phase 2 | 2019-09-25 |
| Unknown | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carc Merkel Cell Carcinoma | Phase 1 / Phase 2 | 2019-03-19 |
| Unknown | KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Ref Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF) | Phase 2 / Phase 3 | 2019-01-15 |
| Unknown | KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera Polycythemia Vera | Phase 2 | 2019-01-15 |
| Completed | A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma Advanced Malignancy, Advanced Solid Tumors, Cancer | Phase 1 | 2014-12-19 |
| Completed | A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia Advanced Malignancy, Cancer, Oncology | Phase 1 | 2014-04-01 |
| Completed | A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma Advanced Malignancy, Advanced Solid Tumors, Cancer | Phase 1 | 2012-12-27 |